Stick to baseball, 1/25/20.

I had one piece for the Athletic this week, on Atlanta’s signing of Marcell Ozuna. I held a Klawchat on Friday.

My second book, The Inside Game: Bad Calls, Strange Moves, and What Baseball Behavior Teaches Us About Ourselves, is due out on April 21st from Harper Collins, and you can pre-order it now via their site or wherever fine books are sold. I also sent out a fresh edition of my free email newsletter this week, revealing my Hall of Fame ballot.

And now, the links…

Stick to baseball, 1/18/20.

I’ve written five pieces for the Athletic so far over the two weeks since I joined. In reverse chronological order, they are a ranking of the ten best prospects to change organizations this winter; a breakdown of the Josh Donaldson signing; a breakdown of last week’s Rays-Cardinals trade; notes on what I look for when evaluating players; and my introductory post. I also held a Klawchat this week.

Over at Paste, I reviewed The Taverns of Tiefenthal, the newest game from Kennerspiel des Jahres winner Wolfgang Warsch, who also designed The Mind, That’s Pretty Clever!, and The Quacks of Quedlinburg, all of which are quite good.

My second book, The Inside Game: Bad Calls, Strange Moves, and What Baseball Behavior Teaches Us About Ourselves, is due out on April 21st from Harper Collins, and you can pre-order it now via their site or wherever fine books are sold. You can also sign up for my free email newsletter for even more non-baseball content.

And now, the links…

  • Longreads first: Slate has the story of a credible allegation of rape against three Mets from the spring of 1991, with Doc Gooden, Daryl Boston, and Vince Coleman all accused. None was ever charged.
  • The Root and the Young Turks detail outright racism in the South Bend police force under Pete Buttigieg. The details herein, and Mayor Pete’s unwillingness to answer basic questions about them, are quite damning.
  • Did an Oxford classics professor steal and sell ancient pieces of papyrus, including one that would be the oldest known piece of the gospels, to the billionaire owners of Hobby Lobby?  (Also, how can you be a billionaire and a devout Christian? I’m reasonably sure Jesus said those two things could not be true at the same time.)
  • The New Yorker looks at a woman who can’t feel physical or emotional pain due to a genetic mutation, and whether the extent to which we feel pain is really an essential part of being human.
  • The New York Times describes how a recently-deceased real estate ‘star’ lied about her entire biography.
  • Peter Hotez, author of Vaccines Did Not Cause Rachel’s Autism, writes about how sick you’re going to get if you catch various vaccine-preventable diseases. It’s not pretty, and it’s all the more argument for tightening vaccination laws for schoolchildren.
  • Here’s a shocker: Gwyneth Paltrow’s new GOOP show on Netflix is a mixture of pseudoscience, bullshit, and tedium, including an episode with a so-called “energy healer” (which is not real) and another with a self-proclaimed psychic (also not real).
  • Michigan state senator Peter Lucido, who has delusions of governorship, told a woman journalist trying to interview him that a group of high school boys “could have a lot of fun” with her. As of Friday, he’s issued a half-assed apology, but remains in office.
  • The New Yorker talks to the two people behind the great @NJGov twitter account.
  • Writing for VICE, Laura Wagner (ex-Deadspin) writes about the Facebook ‘sponsored post’ fiasco at Teen Vogue.
  • A British Columbia court ruled that two young children must be vaccinated over their mother’s objections. The mother tried to cite one of the most vocal anti-vaccine cranks on Twitter, Toni Bark, who claimed the measles wasn’t a highly contagious disease (it’s considered the most or second-most contagious virus humans can catch).
  • Perhaps “cocktails” of multiple antibiotics aren’t as good of an idea for the long term as we thought, as one new study shows that they may accelerate antibiotic resistance.
  • Tabatha Southey writes for McLean’s about Watergate, my #3 game of 2019, and what a future board game of the Donald Trump presidency and impeachment might look like.
  • I’ve got four new board game Kickstarters to share this week. First is the one I tweeted about on Tuesday, Restoration Games’ Return to Dark Tower, which is already clear of $2.25 million pledged as of Friday afternoon. It’s an update to the 1981 cult classic, and I was hooked when I saw the demo at PAX Unplugged.
  • Next is AlderQuest, an area-control game from Rock Manor Games and Mike Gnade (Set a Watch, Brass Empire). Rock Manor pulled the original Kickstarter from before the holidays and restarted it; it’s about 2/3 of the way to its funding goal as I write this. Full disclosure: I met Mike this week to play an upcoming Rock Manor title, Lawyer Up, as he lives a stone’s throw from me.
  • Leder Games has the newest game from designer Cole Wehrle (Root, Pax Pamir), Oath: Chronicles of Empire and Exile, already more than 13 times past its initial goal.
  • Vesuvius Media has a Kickstarter up for Pacific Rails, a route-building/worker-placement game based on the completion of the first transcontinental railroad in 1869.
  • Finally, here’s an intriguing game of dirty popes: Habeamus, which the publishers describe as “a game for ending 2-4 friendships. This is the farthest from its goal of these five Kickstarters right now.

Stick to baseball, 9/7/19.

I had one ESPN+ piece this week, looking at the best or most interesting September prospect callups. I also held a Klawchat on Thursday.

For Paste, I reviewed Planet, a simple tile-laying game where you place those tiles on your own polyhedron planet, so you get to hold the whole world in your hands.

Now that this piece is done and I’ve already filed my ESPN column for next week (Prospect of the Year), I’ll work on my next email newsletter. You can sign up for free any time.

I’m selling off some of my board games, and once again I’m donating all proceeds to the Food Bank of Delaware. You can see the games I’m selling here. Thanks to those of you who’ve already bought some of my games, I’ve donated over $330 to the Food Bank.

And now, the links…

Bad Blood.

Theranos was one of the hottest tech startups of the last fifteen years, at least in terms of the breathless coverage afforded to the company’s putative blood-testing technology and young founder and CEO, Elizabeth Holmes. As you know by now, the entire thing was a giant fraud: the technology never worked, the company ducked or lied to regulators, and Holmes in particular lied to the press and investors who plowed a few hundred million dollars into the company before it collapsed. That implosion came about thanks to a few whistleblowers from inside the firm and the diligent reporting of Wall Street Journal journalist John Carreyrou, who tells the entire history of the scam in his book Bad Blood. The book is thorough, gripping, and infuriating: how did one inexperienced college dropout manage to con so many ostensibly intelligent people into believing her bullshit?

Theranos’s claim was that they could run over a hundred tests on just a single drop of blood drawn by a fingerstick by using a relatively minuscule device, first one called the Edison and later one called the miniLab, that could live in a doctor’s office, a pharmacy clinic, or even a patient’s home. This included routine tests like those for blood cholesterol levels as well as more complex tests that would ordinarily require a lot more blood, which would have to be drawn from a vein. None of this ever worked, and Theranos hid the fraud by taking blood samples back to its headquarters and running the samples on larger machines made by Siemens, all the while making increasingly grandiose claims about its technology, forging nine-figure partnerships with Walgreens and Safeway, and continuing to solicit investments at valuations that eventually crossed $5 billion, making Holmes a paper billionaire.

The media coverage of Theranos in general and Holmes in particular was willfully credulous, none more so than the Fortune cover story “This CEO’s Out for Blood,” a fawning profile that bought all of Holmes’ lies wholesale with what appears to be no attempt to independently validate any of her claims. (The writer, Roger Parloff, eventually admitted he’d been duped.) Holmes appears to have had a strategy for executing this con by co-opting the reputations of powerful, older men: she managed to pack her board with major political figures, including George Schultz and Gen. James Mattis, who all tended to be old white men with zero scientific or technical background, but whose presence carried a lot of weight with the media. She also hired attorney David Boies, eventually giving him shares in the company and a board seat, to stage scorched-earth attacks on anyone who dared criticize the company, which included intimidating former employees who might reveal that Theranos’ technology didn’t work. She even landed a spot as an Ambassador for Global Entrepreneurship for the Obama Administration, only stepping down months after the fraud was revealed.

Carreyrou didn’t buy it, and he didn’t back down, all of which shows in his WSJ articles that dismantled the company’s house of lies and again shows in Bad Blood, which is meticulous in reconstructing the genesis and perpetuation of the fraud, with information gleaned from over 150 interviews with employees and others close to Theranos. He particularly benefited from information from Tyler Schultz, George Schultz’s grandson and a Theranos employee for about a year, who realized that Theranos’ technology didn’t work and that they weren’t properly verifying their results (but were still making the same claims of accuracy to the public), and who reported the company to regulators despite intense pressure and outright threats from Theranos, its lawyers, and his own family. (Schultz, who will turn 99 later this year, was a true believer in Theranos and in Holmes until well after the fraud was made public.) Bad Blood is full of details of internal interactions from Theranos that depict Holmes and COO Ramesh “Sunny” Balwani as vindictive, paranoid bullies who didn’t care that the technology didn’t work, or simply refused to accept that it didn’t, and thought they could steamroll anyone who tried to get in their way – and for about a decade, it worked.

The overwhelming sense Bad Blood gave me is that so very many of the people involved in the scam belong in jail. Holmes and Balwani, who was also her boyfriend when she hired him, come across as sociopaths who relentlessly bullied employees and the media; both are still facing criminal charges, while Holmes settled SEC fraud charges while Balwani is fighting them. They had many allies in their scheme, from Boies (whose behavior seems unethical, at least) to the various marketing and PR flacks inside and outside Theranos who helped perpetuate the con. Does Chiat Day, the major advertising agency Theranos hired to build its image, bear any responsibility for helping disseminate untruths about the company? What about Theranos’ marketing employees or in-house attorneys, the former repeating the lies Holmes and Balwani told them, the latter using dubious tactics to intimidate former employees into signing agreements against their own interests? If Holmes and Balwani actually serve jail time – I’m skeptical, but there’s still a nonzero chance of that – it may deter some future mountebanks, but the biggest lesson of Bad Blood seems to be how many people happily went along with the scheme because they thought Theranos was going to make them rich, and because there was little direct cost to them. Patients could have died from errant medical directions that came from Theranos’ inaccurate test results, yet just about every person involved in promulgating the swindle walked away with nothing worse than a bad name on their resumes.

Carreyrou raises the most salient point that investors and reporters missed during Theranos’ days as a high-flying simurgh: the venture capital firms backing Theranos focused on high tech, but not on biotech or medical devices. The VCs with expertise in medical investments were absent. Carreyrou argues that that should have set off alarm bells for other investors or for reporters racing to laud the company or its female founder/CEO, who benefited from the media’s desire to find a rare woman among Silicon Valley leaders, from her photogenic looks, and from her overt attempts to channel Steve Jobs (which come off as delusionally creepy in the book). Con artists will never lack for marks, but when the people who would ordinarily be most interested in backing a venture head in the other direction, it should serve as at least a prompt to ask more probing questions before putting the CEO on your magazine’s cover.

Next up: I’m preparing for the upcoming amazon series by reading Terry Pratchett & Neil Gaiman’s novel Good Omens.

Stick to baseball, 8/25/18.

I had one Insider/ESPN+ piece this week, scouting notes on Tampa wunderkind Wander Franco and some Yankees & Rangers prospects, and held a Klawchat on Thursday.

I reviewed the gladiator-themed deckbuilding game Carthage for Paste this week. That’s the last of my pre-Gen Con reviews; I believe everything I review the rest of the year will either be from games I got/saw at Gen Con or that were released afterwards.

I’m about due for a fresh edition of my free email newsletter, to which you may wish to subscribe if you enjoy my ramblings.

And now, the links…

Big Chicken.

Antibiotic resistance doesn’t get a ton of headlines, but it is one of the most critical threats to global health, enough so that the United Nations resolved to address the problem at a summit late in 2016. At the time, they estimated there would be 10 million deaths annually from resistant ‘superbugs’ by the year 2050, which doesn’t include people who would die indirectly from the scourge, such as people who can’t have surgery because the antibiotics that you receive before any operation are no longer effective. In a country where a third of the population rejects the truth of evolution, getting people to understand this issue – itself the product of evolutionary processes among bacteria – has been difficult, and never seems to rise very high on the priority lists for policymakers.

Maryn McKenna’s new book Big Chicken: The Incredible Story of How Antibiotics Created Modern Agriculture and Changed the Way the World Eats, the journalist and Schuster Institute fellow explains how we got here by way of the humble chicken, which took over our plates and menus thanks to the prodigious and reckless use of antibiotics, in turn leading to widespread antibiotic resistance in our food supply and outside of it as well. Chicken became an industrial product because someone realized that pumping birds full of antibiotics as part of their feed would make them grow faster, regardless of whether they had any need for these medications. While the chicken world consolidated and counted its profits, bacteria did what they do – evolved, through mutations and gene transfer, to become resist to one drug after another, spreading through and beyond our food supply, abetted by antibiotic residues that washed into the water supply from overuse.

McKenna builds the book around the narrative of one man who nearly died from salmonellosis, an infection caused by bacteria in the Salmonella genus (there are two species, and either can cause this illness), part of a widespread 2013 outbreak caused by unsanitary conditions at the Foster Farms chicken processing plant. The specific Salmonella strain in this outbreak, known as Heidelberg, was resistant to multiple antibiotics, sickened over 600 people, and resulted in at least 200 hospitalizations, although there were no reported deaths. Within the framework of this patient’s ordeal – he survived, but will have lifelong complications, which is common for people who develop these infections – McKenna walks through the history of the chicken as foodstuff, from its advent as an industrial product through changes to the bird to the very recent movement by major chicken producers and consumers to stop antibiotic use.

The very rise of this form of industrialized animal husbandry was an accident, which is one of the book’s most interesting sections (granted, I love history of science stories); there wasn’t any reason to think pumping healthy birds full of antibiotics would make them grow faster, but it did, to a shocking extent. What is infuriating, if not entirely surprising, is how government agencies responsible for ensuring public health rolled over and played dead for Big Chicken and the antibiotic manufacturers themselves even as scientists began to sound alarms about resistant bacteria in the 1950s. The manufacturers played the Big Tobacco game of demanding more proof, aided and abetted by Congressman Jamie Whitten, a Democrat from Mississippi, who abused his power to protect the two industries from proposed restrictions on antibiotic usage until his retirement in 1994. (Whitten wrote a pro-pesticide screed as a rejoinder to Rachel Carson’s Silent Spring, in case you were unclear on his stance on the matter.) Mckenna parallels this narrative with a walk through the tactics of the bacterial world to outflank our best drugs, most recently with the emergence of bacteria with the mcr-1 gene, conferring resistance to colistin, an antibiotic of ‘last resort’ that has been used for bacteria resistant to all other antibiotics.

Blaming the two industries of chicken and pharma, along with the complicity of useless government agencies (the FDA and the USDA), is easy, but the American consumer is also a major part of the problem here. We eat far more meat than we need to meet our dietary requirements, but we insist on meat being cheap, which encourages us to both eat and waste more of it. We’ve also decided we want lean meat, based on nutritional advice from the Useless Department of Agriculture that turned out to be mostly to entirely wrong, leading to greater demand for breast meat, and in turn for farmers to grow chickens with giant breasts and smaller legs, to the point that the broiler-fryer chickens you might get in an average grocery or warehouse store can’t walk or stand up normally. (I rarely see them in stores, but once did buy a pasture-raised whole chicken; it had less than half the breast meat of even a well-raised conventional bird.) McKenna goes into this in more detail – how the rise of ‘chicken fingers’ and the McNugget exacerbated this trend, how consumers prefer buying chicken parts rather than whole birds – while also pointing out how producers bred birds with these un-natural characteristics to suit the marketplace.

There is hope, at least in this book, on both the antibiotic resistance and the chicken-producing fronts. The UN has, at least, paid lip service to the cause of fighting antibiotic resistance. Several major chicken producers, led by Purdue, have stopped or pledged to stop using antibiotics in full, or to only use them to treat sick birds rather than as growth promoters or for prophylactic purposes. Many large chicken buyers, including Panera, Chipotle, and even McDonald’s, have also pledged to go antibiotic-free, or have done so already. Whole Foods has long been antibiotic-free as well. (One reason I buy organic milk and eggs, even though ‘organic’ itself isn’t that meaningful: It guarantees the cows/birds in question weren’t given antibiotics.) And slowing the use of antibiotics on animals should help in particular if and when researchers discover the next big class of antibiotic compounds. We may have gotten much farther with the drugs we had if we hadn’t given them in such huge quantities to the animals we raised and ate.

McKenna also visits chicken farmers who are operating outside of the main supply chain of industrial birds, raising heirloom varieties in the American heartland or raising certified Label Rouge birds in France, chickens that neither look nor taste like the bland if predictable American hybrids. Educating consumers with the disposable income to buy these birds is a challenge, but one that has plenty of precedent in the market for high-end foods. The bigger conundrum is how to provide enough meat, chicken or otherwise, to feed a world that increasingly demands it and doesn’t want to pay more for it, without the overuse of antibiotics that has led us to the edge of a bottomless pit of resistance.

Next up: Dan Simmons’ The Fall of Hyperion.

The Emperor of All Maladies.

Siddhartha Mukherjee, an Indian-born American oncologist who trained at the Dana-Farber Cancer Institute in Boston, won the Pulitzer Prize for Non-Fiction for his 2010 tome The Emperor of All Maladies: A Biography of Cancer, his first book and an enormous undertaking – an exhaustive attempt to chronicle the history of the disease itself and the ongoing scientific fight to cure it. Interspersed with anecdotes from his own oncology work, including several patients he treated – some who survived the disease, and many who did not – Emperor covers a truly incredible amount of ground, often with more detail than I needed to understand the story, and presents a sobering picture of how endless the efforts to treat and cure cancer will be, given the disease’s nature and ability to defeat our best weapons against it.

Mukherjee goes back to ancient Egypt and Greece to give us the earliest known examples of the disease’s appearance and explain how it got its name – it’s from the Latin word meaning ‘crab,’ and the word carcinoma comes from the Greek word for the same – but the bulk of the history in this book starts in the mid-19th century with the first real identification of a specific cancer, leukemia. The story wends its way through the late part of that century with the advent of radical mastectomies to remove breast cancer, disfiguring surgeries that would remove many muscles beyond the breasts and that were the brainchild of the coke-addicted surgeon William Halsted, who also conceived the modern residency program for new doctors that forces them to operate without sleep. We get the discovery that radiation causes cancer, and the related discovery that it might treat cancer as well, as would certain drugs that we now put under the umbrella of chemotherapy. Mukherjee takes the science thread all the way through what were, at the time, the latest developments in oncology treatment and research, including the ongoing identification of oncogenes (genes that, when switched ‘on,’ can produce cancer), proto-oncogenes (genes that become oncogenes with mutations), and anti-oncogenes (tumor-suppressing genes); and therapies that target specific cancer subtypes based on their genotypes – such as Herceptin, which has proven exceptionally effective against breast and other cancers cancer with the HER2 oncogene.

The science bits – my favorite, of course – are interspersed with much of the story of the American public policy fight over cancer, which led to a so-called “War on Cancer,” the passage of the 1971 National Cancer Act to boost the National Cancer Institute, and many breathless pronouncements that we were mere years away from finding a cure. The narrative lags at several points here – the origin story of the Jimmy Fund’s “Jimmy,” real name Einar Gustafson, is the big exception – although it serves as a reminder of how credulous the world was, including early researchers into oncology, about our ability to ‘beat’ or cure cancer. Cancer is not just one disease; it is many, probably hundreds, of diseases that all share the common characteristic of abnormal cell growth, but that can differ substantially by their origin in the body, and even for a specific source or organ can come in vastly diverse forms that require different, targeted treatments. The above-mentioned Herceptin works on HER2+ cancers, mostly breast cancer but sometimes appearing in gastric or ovarian cancers; it will be ineffective against HER2-negative cancers. Someone with ‘breast cancer’ can have any of several forms of the disease – each of which will respond in totally different ways to treatments. This is good news and bad news; the more we know about specific forms of cancer, the better that scientists can come up with targeted treatments to attack them, but there are also far more forms of cancer than we’d ever realized in the history of our fight against the disease. The single ‘cure for cancer’ is probably a chimera, because cancer is not just one thing, but a common attribute of many diseases, and stopping that attribute – rampant cell division – would kill regular cells too.

The Emperor of All Maladies is kind of a depressing read, between the awful outcomes for some of the patients described, but also because the outlook for the future of the disease is not that great. Yes, the medical world continues to search for and find treatments for specific cancers, some of which are the most effective drugs in the history of oncology, but it’s also clear that if your specific cancer isn’t one of those, the medical response is the same drug cocktail approach that has been the norm for decades – better than it was, and with the benefit of drugs to help combat nausea, but still an ordeal for the patient with modest success rates. And finding Herceptin-like advances for all cancers will take many years and billions of dollars that may not be available without a massive public investment. Dr. Mukerjee has put together a remarkable work of research and insight, written with great feeling for the individual patients fighting their cancers, but I left this book feeling worse about the war on cancer than I ever had before.

Next up: Dan Simmons’ The Fall of Hyperion.